Cargando…

MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer

The treatment of high-risk prostate cancer (HRPCa) is a tremendous challenge for uro-oncologists. The identification of predictive moleculobiological markers allowing risk assessment of lymph node metastasis and systemic progression is essential in establishing effective treatment. In the current st...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalogirou, Charis, Spahn, Martin, Krebs, Markus, Joniau, Steven, Lerut, Evelyne, Burger, Maximilian, Scholz, Claus-Jürgen, Kneitz, Susanne, Riedmiller, Hubertus, Kneitz, Burkhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856012/
https://www.ncbi.nlm.nih.gov/pubmed/24173237
http://dx.doi.org/10.3390/ijms141121414
_version_ 1782294999426138112
author Kalogirou, Charis
Spahn, Martin
Krebs, Markus
Joniau, Steven
Lerut, Evelyne
Burger, Maximilian
Scholz, Claus-Jürgen
Kneitz, Susanne
Riedmiller, Hubertus
Kneitz, Burkhard
author_facet Kalogirou, Charis
Spahn, Martin
Krebs, Markus
Joniau, Steven
Lerut, Evelyne
Burger, Maximilian
Scholz, Claus-Jürgen
Kneitz, Susanne
Riedmiller, Hubertus
Kneitz, Burkhard
author_sort Kalogirou, Charis
collection PubMed
description The treatment of high-risk prostate cancer (HRPCa) is a tremendous challenge for uro-oncologists. The identification of predictive moleculobiological markers allowing risk assessment of lymph node metastasis and systemic progression is essential in establishing effective treatment. In the current study, we investigate the prognostic potential of miR-205 in HRPCa study and validation cohorts, setting defined clinical endpoints for both. We demonstrate miR-205 to be significantly down-regulated in over 70% of the HRPCa samples analysed and that reconstitution of miR-205 causes inhibition of proliferation and invasiveness in prostate cancer (PCa) cell lines. Additionally, miR-205 is increasingly down-regulated in lymph node metastases compared to the primary tumour indicating that miR-205 plays a role in migration of PCa cells from the original location into extraprostatic tissue. Nevertheless, down-regulation of miR-205 in primary PCa was not correlated to the synchronous presence of metastasis and failed to predict the outcome for HRPCa patients. Moreover, we found a tendency for miR-205 up-regulation to correlate with an adverse outcome of PCa patients suggesting a pivotal role of miR-205 in tumourigenesis. Overall, we showed that miR-205 is involved in the development and metastasis of PCa, but failed to work as a useful clinical biomarker in HRPCa. These findings might have implications for the use of miR-205 as a prognostic or therapeutic target in HRPCa.
format Online
Article
Text
id pubmed-3856012
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-38560122013-12-09 MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer Kalogirou, Charis Spahn, Martin Krebs, Markus Joniau, Steven Lerut, Evelyne Burger, Maximilian Scholz, Claus-Jürgen Kneitz, Susanne Riedmiller, Hubertus Kneitz, Burkhard Int J Mol Sci Article The treatment of high-risk prostate cancer (HRPCa) is a tremendous challenge for uro-oncologists. The identification of predictive moleculobiological markers allowing risk assessment of lymph node metastasis and systemic progression is essential in establishing effective treatment. In the current study, we investigate the prognostic potential of miR-205 in HRPCa study and validation cohorts, setting defined clinical endpoints for both. We demonstrate miR-205 to be significantly down-regulated in over 70% of the HRPCa samples analysed and that reconstitution of miR-205 causes inhibition of proliferation and invasiveness in prostate cancer (PCa) cell lines. Additionally, miR-205 is increasingly down-regulated in lymph node metastases compared to the primary tumour indicating that miR-205 plays a role in migration of PCa cells from the original location into extraprostatic tissue. Nevertheless, down-regulation of miR-205 in primary PCa was not correlated to the synchronous presence of metastasis and failed to predict the outcome for HRPCa patients. Moreover, we found a tendency for miR-205 up-regulation to correlate with an adverse outcome of PCa patients suggesting a pivotal role of miR-205 in tumourigenesis. Overall, we showed that miR-205 is involved in the development and metastasis of PCa, but failed to work as a useful clinical biomarker in HRPCa. These findings might have implications for the use of miR-205 as a prognostic or therapeutic target in HRPCa. Molecular Diversity Preservation International (MDPI) 2013-10-29 /pmc/articles/PMC3856012/ /pubmed/24173237 http://dx.doi.org/10.3390/ijms141121414 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Kalogirou, Charis
Spahn, Martin
Krebs, Markus
Joniau, Steven
Lerut, Evelyne
Burger, Maximilian
Scholz, Claus-Jürgen
Kneitz, Susanne
Riedmiller, Hubertus
Kneitz, Burkhard
MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer
title MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer
title_full MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer
title_fullStr MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer
title_full_unstemmed MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer
title_short MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer
title_sort mir-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856012/
https://www.ncbi.nlm.nih.gov/pubmed/24173237
http://dx.doi.org/10.3390/ijms141121414
work_keys_str_mv AT kalogiroucharis mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer
AT spahnmartin mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer
AT krebsmarkus mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer
AT joniausteven mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer
AT lerutevelyne mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer
AT burgermaximilian mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer
AT scholzclausjurgen mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer
AT kneitzsusanne mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer
AT riedmillerhubertus mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer
AT kneitzburkhard mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer